abstract |
The present invention generally relates to the diagnosis of cancers having cell surface de-N-acetylated sialic acid antigens, eg, at least partially de-N-acetylated gangliosides and / or de-N-acetylated sialic acid modified cell surface proteins. And / or therapeutic methods and compositions are provided. |